#1HYPERFINEⓇ Brain Imaging Within Reach The Swoop® system is driving the future of brain health. Piper Sandler 35th Annual Healthcare Conference Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#2Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These for ard-looking statements involve significant risks and uncertainties that could cause the act results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. 2 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. HYPERFINEⓇ#3#6 JALCOOG 200kg/44 HYP A First for Brain Health Hyperfine, Inc. has developed and commercialized a unique ultra-low-field portable MR brain imaging system that aims to improve brain health globally. ● Accessible and affordable to clinicians and patients in multiple care settings (from critical care to offices). • Enables clinicians to make timely and early diagnosis of critical brain conditions. ● • Potential to reduce the devastating impact of widespread and increasing global neurological conditions, such as stroke and Alzheimer's disease. HYPERFINEⓇ#4hut Guz Numerous Challenges with Conventional MRI: High-cost and complex site requirements limits access Highly trained personnel constrains capacity Limited availability leads to delayed diagnosis and care Risk of adverse events during inpatient transportation $ 880 HYPERFINE,#5The Swoop System is Ready to Transform Brain Imaging and Improve Brain Health TOGGTU 200kg HYPERF LAIT HYPERFINE AD 15 1826 12 15 7.13 520 70. 25- 46#6The Global Impact of Brain Health Stroke¹ 12.2 million new strokes per year Alzheimer's Disease² 50 million people suffering from dementia (2018 estimate) 1. World Stroke Organization: Global Stroke Fact Sheet 6 152 million people in the world suffering from dementia estimated by 2050 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. $451 billion estimated worldwide cost of stroke in 2017 Over 50% of dementia cases are Alzheimer's disease 2. According to a 2022 article published in the Frontiers in Neurology (doi:10.3389/fncel.2021.811852). HYPERFINEⓇ#7The Swoop System is Ready to Transform Brain Imaging and Improve Brain Health 7 Clinically-relevant images with ultra-low-field MRI Safe at multiple sites of care First mover with proprietary technology (150+ patents) and Al-powered software Platform technology designed for multiple brain imaging applications PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 200kg 430 MAX AA0900 HYPERFINE New ultra-low-field brain imaging paradigm-disrupting access and economics and expanding the conventional MRI market Broad FDA-clearance for brain imaging of patients of all ages Commercially available in the US with reimbursement under existing CPT codes Global footprint through research institutions and the Bill & Melinda Gates Foundation Unity network HYPERFINEⓇ#8The Swoop System Increases Global MRI Capacity by Enabling Brain Imaging Anywhere 8 Current Paradigm Conventional MRI PHILIPS SIEMENS Healthineers New Paradigm HYPERFINE Point of Care PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Tojo Community Access 10 Inpatient Outpatient Pre-hospital Epidemiological Studies ED ICU, Floor Division Clinics Rural / Low Resource Areas Low/Middle Income Countries Courtesy of William T. Kimberly, MD and Kevin Sheth, MD The Swoop system serves multiple sites of care and many applications of significant unmet need globally. Complementary to conventional MRI and existing hospital workflows. HYPERFINE.#9A Dramatic Improvement in Clinical Workflow 55% Time Reduction² 9 The Swoop system streamlines the workflow process to enable timely clinical decisions and reduce risks. Conventional MRI PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 22 Steps 1.0¹-11.2² Hours High Risk Swoop System 3 Steps 0.5-4.5 Hours 1. Mazurek, M.H., Cahn, B.A., Yuen, M.M. et al. Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage. Nat Commun 12, 5119 (2021). https://doi.org/10.1038/s41467-021-25441-6 2. Kuoy et al. Point-of-Care Brain MRI: Preliminary Results from a Single-Center Retrospective Study. Radiology 2022 https://doi.org/10.1148/radiol.211721 Low Risk HYPERFINE.#10Advancing the Care Experience for All 10 Hyperfine, Inc. is at the forefront of making healthcare more connected, portable, patient-centric, and accessible in less resource-intensive settings. 1 Patients Because empowered patient choices matter. BO PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Clinicians and Care Teams Because timely decisions and personalized care matter. Hospitals Because resources and cost matter. HYPERFINEⓇ#11Immediate Clinical Applications, Blueprint for Continued Growth Current Commercial and Clinical Applications Clinical Research and R&D for Future Applications 11 The Swoop system expands the fast growing (6% annual CAGR) $35 billion global imaging market. Critical Care Pediatrics Stroke PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Alzheimer's Global Expansion Future Opportunities Remote Care Preventive Care HYPERFINE.#12Three Strategic Pillars for Growth 12 Innovation HYPERFINE PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Clinical Evidence Ⓡ Commercialization HYPERFINEⓇ#13Innovation: Proven Record of Releasing New Technology to the Market D 13 2020 C Al-powered Imaging ✔ 2021 Sy ololo 101100 Hardware (1.7) and software (8.1): Brain imaging for all ages. 010110 101100 Hardware (1.6) and software (8.0): The world's first bedside MRI system for brain imaging of patients ages 2 and up. 2022 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. au Hardware (1.8) and software (8.2): Additional automatic alignment and motion correction features. 010110 Holloo 2023 010110 01100 Software (8.3): Elevated diagnostic value: advanced image reconstruction leveraging deep learning for T1, T2, and FLAIR sequences. ● 010110 01100 Software (8.6): Significant DWI improvements, Advanced motion compensation. Software (8.5): DWI image quality improvement, improved intensity uniformity, faster image acquisition. Hardware (1.9): Updates to hardware components and minimum patient weight limit. Software (8.4): Fast T2: 50% faster option to the existing higher-quality T2 sequence. T1 (Standard): better intraparenchymal visibility, improved noise cancellation. Software (8.7): Al denoising in DWI sequence. E *Not yet commercialized. Broad indication for imaging of the brain (all ages). Nine FDA clearances for the Swoop system in the last 36 months. CE certification achieved under latest MDR regulations. HYPERFINE.#14Clinical Evidence: Thirty-four Peer-reviewed Publications to Date and Significant Investment in Studies in New Clinical Use Cases 14 Current Commercial and Clinical Applications m Critical Care Pediatrics 13 publications HOPE PMR (Hydrocephalus) Clinical Research and R&D for Future Applications PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Stroke Alzheimer's 15 publications Ongoing Prospective Studies ACTION PMR (Stroke) SAFE MRI (ECMO) Future Opportunities Remote Care New Use Cases 6 publications HYPERFINEⓇ#15Commercialization 15 Today ZIN ZIN US direct sales team with distributors in Canada, Australia, New Zealand, and Pakistan PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Next 24 Months European Union expansion > 24 Months Global expansion HYPERFINEⓇ#16Solid Foundation for Long Term Success User-centric Ecosystem: Scalable and Low-cost 16 Connectivity to integrate across radiology information systems Over-the-air software upgrades to enable rapid enhancements Cloud for image and data viewing PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. M (H) Cybersecurity: HITRUST and SOC2 type1 certifications Remote technical support and service to maximize customer uptime HYPERFINEⓇ#17Strong Financial Position to Fuel Future Growth Revenue $0.30 2020 $1.50 $6.80 2021 2022 Revenue in Millions *2023 revenue guidance: $11M to $13M $11-$13* 2023 17 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Growth Drivers: • Swoop system sales: Maturing ● commercial team and broadening use cases across critical care and pediatrics. • Pricing ● Service revenue ● HYPERFINEⓇ#18Strong Financial Position to Fuel Future Growth Gross Margin 2021 18 -80% *2023 gross margin guidance: 44% to 46%. 13% 2022 Gross Margin % 44%-46%* 2023 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Growth Drivers: • Achieving significant leverage through ● commercialization, cost control, and Swoop system pricing. HYPERFINEⓇ#19Strong Financial Position to Fuel Future Growth Cash Burn $71 19 2022 *2023 cash burn guidance: $41to $44 million. $41-$44* Cash Burn In Millions 2023 Reducing cash burn with runway through 2025 while focusing spend on three strategic pillars: Innovation: Hardware and software (Al) updates. • Clinical evidence: Expanding clinical applications. ● PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. ● • Commercialization: Building the pipeline for US Swoop system sales. Cash and Cash Equivalents of $85.4M as of September 30, 2023 HYPERFINE.#20Hyperfine, Inc. Leadership Team Brings a Proven Track Record of Success 20 Maria Sainz President & Chief Executive Officer PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Brett Hale Chief Administrative Officer and Chief Financial Officer Tom Teisseyre Chief Operating Officer HYPERFINEⓇ#21The Hyperfine, Inc. Opportunity 21 BO First FDA-cleared portable ultra-low-field MR brain imaging system expanding a multi-billion- dollar market Commercial stage company expanding the brain imaging market to solve for substantial unmet provider and patient need Prolific engine of fast innovation and clinical evidence based on strong proprietary technology PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. OB %d0% Platform technology with significant greenfield opportunities in neurocritical care, hydrocephalus, stroke, and Alzheimer's Early track record of rapid topline and gross margin growth with healthy cash runway Highly experienced executive team with deep industry expertise HYPERFINEⓇ#22HYPERFINE. Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#23Clinical Publications Identification of White Matter Hyperintensities in Routine Emergency Department Visits Using Portable Bedside Magnetic Resonance Imaging. de Havenon A, Parasuram NR, Crawford AL, et al. J Am Heart Assoc. 2023;12(11):e029242. doi:10.1161/JAHA.122.029242 In vivo quantitative MRI: T1 and T2 measurements of the human brain at 0.064 T. Jordanova KV, Martin MN, Ogier SE, Poorman ME, Keenan KE. MAGMA. 2023;10.1007/s10334-023-01095-x. doi:10.1007/s10334-023- 01095-x Feasibility of bedside portable MRI in neonates and children during ECLS. Sabir H, Kipfmueller F, Bagci S, et al. Crit Care. 2023;27(1):134. Published 2023 Apr 4. doi:10.1186/s13054-023-04416-7 Feasibility of and experience using a portable MRI scanner in the neonatal intensive care unit. Sien ME, Robinson AL, Hu HH, et al. Arch Dis Child Fetal Neonatal Ed. 2023;108(1):45-50. doi:10.1136/archdischild-2022- 324200 In vivo T1 mapping of neonatal brain tissue at 64 mT. Padormo F, Cawley P, Dillon L, et al. Magn Reson Med. 2023;89(3):1016-1025. doi:10.1002/mrm.29509 Quantitative Brain Morphometry of Portable Low-Field-Strength MRI Using Super-Resolution Machine Learning. Iglesias JE, Schleicher R, Laguna S, et al. Radiology. 2023;306(3):e220522. doi:10.1148/radiol.220522 Neuroimaging and verbal memory assessment in healthy aging adults using a portable low-field MRI scanner and a web-based platform: results from a proof-of-concept population-based cross-section study. Deoni SCL, Burton P, Beauchemin J, et al. Brain Struct Funct. 2023;228(2)L493-509. doi:10.1007/s00429-022-02595-7 Dual-domain self-supervised learning for accelerated non-Cartesian MRI reconstruction. Zhou B, Schlemper J, Dey N, et al. Med Image Anal. 2022;81:102538. doi:10.1016/j.media.2022.102538 Portable, low-field magnetic resonance imaging enables highly accessible and dynamic bedside evaluation of ischemic stroke. Yuen MM, Prabhat AM, Mazurek MH, et al. Sci Adv. 2022;8(16):eabm3952. doi:10.1126/sciadv.abm3952 Safety of Bedside Portable Low-Field Brain MRI in ECMO Patients Supported on Intra-Aortic Balloon Pump. Wilcox C, Acton M, Rando H, et al. Diagnostics (Basel). 2022;12(11):2871. Published 2022 Nov 19. doi:10.3390/diagnostics 12112871 Bedside detection of intracranial midline shift using portable magnetic resonance imaging. Sheth KN, Yuen MM, Mazurek MH, et al. Sci Rep. 2022;12(1):67. Published 2022 Jan 7. doi:10.1038/s41598-021-03892-7 23 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Simultaneous high-resolution T2-weighted imaging and quantitative T2 mapping at low magnetic field strengths using a multiple TE and multi-orientation acquisition approach. Magnetic Resonance in Medicine. Deoni SCL, O'Muircheartaigh J, Ljungberg E, Huentelman M, Williams SCR. Magn Reson Med. 2022;88(3):1273- 1281. doi:10.1002/mrm.29273 Development of a mobile low-field MRI scanner. Deoni SCL, Medeiros P, Deoni AT, et al. Sci Rep. 2022;12:5690. doi:10.1038/s41598-022-09760-2 Assessing the SAfety and FEasibility of bedside portable low-field brain Magnetic Resonance Imaging in patients on ECMO (SAFE-MRI ECMO study): study protocol and first case series experience. Cho S-M, Wilcox C, Keller S, et al. Critical Care. 2022;26:119. doi:10.1186/s13054-022-03990-6 Bedside monitoring of hypoxic ischemic brain injury using low-field, portable brain magnetic resonance imaging after cardiac arrest. Beekman R, Crawford A, Mazurek MH, et al. Resuscitation. 2022;176:150-158. doi:10.1016/j.resuscitation.2022.05.002 Sensitivity of Portable Low-Field Magnetic Resonance Imaging for Multiple Sclerosis Lesions. Arnold TC, Tu D, Okar SV, et al. Neurolmage: Clinical. 2022:103101. doi:10.1016/j.nicl.2022.103101 Simulated diagnostic performance of low-field MRI: Harnessing open-access datasets to evaluate novel devices. Arnold TC, Baldassano SN, Litt B, Stein JM. Magnetic Resonance Imaging. 2022;87:67-76. doi:10.1016/j.mri.2021.12.007 Methodology for Low-Field, Portable Magnetic Resonance Neuroimaging at the Bedside. Prabhat AM, Crawford AL, Mazurek MH, et al. Frontiers in Neurology. 2021;12:2191. doi:10.3389/fneur.2021.760321 Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage. Mazurek MH, Cahn BA, Yuen MM, et al. Nat Commun. 2021;12:5119. doi:10.1038/s41467-021-25441-6 Accessible pediatric neuroimaging using a low field strength MRI scanner. Deoni SCL, Bruchhage MMK, Beauchemin J, et al. Neurolmage. 2021;238:118273. doi:10.1016/j.neuroimage.2021.118273 Portable Magnetic Resonance Imaging for ICU Patients. Crit Care. Turpin J, Unadkat P, Thomas J, et al. Explor. 2020;2:e0306-e0306. doi:10.1097/CCE.0000000000000306 Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients. Sheth KN, Mazurek MH, Yuen MM, et al. JAMA Neurol. 2020. doi:10.1001/jamaneurol.2020.3263 HYPERFINE.#24Clinical Publications Managing Patients with Unlabeled Passive Implants on MR Systems Operating Below 1.5 T. Shellock, F., Rosen, M., Webb, A., et al. Journal of Magnetic Imaging. 2023. doi:10.1002/jmri.29002 A Novel Portable, Mobile MRI: Comparison with an Established Low-Field Intraoperative MRI System. Bossert, S., Unadkat, P., Sheth, K., Asian J Neurosurg. 2023. doi:10.1055/s-0043-1760857 Potential application of ultra-low field portable MRI in the ICU to improve CT and MRI access in Canadian hospitals: a multi-center retrospective analysis. Islam, O., Lin, A., Bharatha, A. Frontiers in Neurology. 2023. doi:10.3389/fneur.2023.1220091 Mobile point-of-care MRI demonstration of a normal volunteer in a telemedicine-equipped ambulance. Roberts, D., McGeorge, T. Abrams, D., et al. Journal of Stroke and Cerebrovascular Diseases. 2023 doi:10.1016/j.jstrokecerebrovasdis.2023.107301 Low-Field Portable Magnetic Resonance Imaging for Post-Thrombectomy Assessment of Ongoing Brain Injury. Stroke: Vascular and Interventional Neurology. Sujijantarat N, Koo AB, Jambor I, et al. Stroke: Vascular and Interventional Neurology. 2023;3(5):e000921. doi:10.1161/SVIN.123.000921 Iron oxide nanoparticles as positive T1 contrast agents for low-field magnetic resonance imaging at 64 mT. Oberdick, S.D., Jordanova, K.V., Lundstrom, J.T. et al. Sci Rep. 2023. 13, 11520. doi:10.1038/s41598-023-38222-6 Towards a barrier-free anthropomorphic brain phantom for quantitative magnetic resonance imaging: Design, first construction attempt, and challenges. Kraft, M., Ryger, S., Berman, B., et al. PLoS ONE. July 2023. 18(7): e0285432. doi:10.1371/journal.pone.0285432 Feasibility and Cost Analysis of Portable MRI Implementation in a Remote Setting in Canada. Canadian Journal of Neurological Sciences. DesRoche CN, Johnson AP, Hore EB, et al. Canadian Journal of Neurological Sciences. 2023:1-10. doi:10.1017/cjn.2023.250 Portable MRI to assess optic chiasm decompression after endoscopic endonasal resection of sellar and suprasellar lesions. Hong CS, Lamsam LA, Yadlapalli V, et al. J Neurosurg. 2023;1-7. doi:10.3171/2023.5JNS23174 Intraoperative use of Ultra-Low-field, Portable MRI - First report. Altaf A, Baqai MWS, Urooj F, et al. Surg Neurol Int. 2023;14:212. Published 2023 Jun 23. doi:10.25259/SNI_124_2023 Image quality assessment of advanced reconstruction algorithm for point-of-care MRI scanner. Krupinski EA, Harris D, Arlinghaus LR, Schlemper J, Sofka M. J Med Imaging (Bellingham). 2023;10(Suppl 1):S11913. doi:10.1117/1.JMI.10.S1.S11913 24 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Identification of White Matter Hyperintensities in Routine Emergency Department Visits Using Portable Bedside Magnetic Resonance Imaging. de Havenon A, Parasuram NR, Crawford AL, et al. J Am Heart Assoc. 2023;12(11):e029242. doi:10.1161/JAHA.122.029242 In vivo quantitative MRI: T1 and T2 measurements of the human brain at 0.064 T. Jordanova KV, Martin MN, Ogier SE, Poorman ME, Keenan KE. MAGMA. 2023;10.1007/s10334-023-01095-x. doi:10.1007/s10334-023- 01095-x Feasibility of bedside portable MRI in neonates and children during ECLS. Sabir H, Kipfmueller F, Bagci S, et al. Crit Care. 2023;27(1):134. Published 2023 Apr 4. doi:10.1186/s13054-023-04416-7 Feasibility of and experience using a portable MRI scanner in the neonatal intensive care unit. Sien ME, Robinson AL, Hu HH, et al. Arch Dis Child Fetal Neonatal Ed. 2023;108(1):45-50. doi:10.1136/archdischild-2022- 324200 In vivo T1 mapping of neonatal brain tissue at 64 mT. Padormo F, Cawley P, Dillon L, et al. Magn Reson Med. 2023;89(3):1016-1025. doi:10.1002/mrm.29509 Quantitative Brain Morphometry of Portable Low-Field-Strength MRI Using Super-Resolution Machine Learning. Iglesias JE, Schleicher R, Laguna S, et al. Radiology. 2023;306(3):e220522. doi:10.1148/radiol.220522 Neuroimaging and verbal memory assessment in healthy aging adults using a portable low-field MRI scanner and a web-based platform: results from a proof-of-concept population-based cross-section study. Deoni SCL, Burton P, Beauchemin J, et al. Brain Struct Funct. 2023;228(2) L493-509. doi:10.1007/s00429-022-02595-7 Dual-domain self-supervised learning for accelerated non-Cartesian MRI reconstruction. Zhou B, Schlemper J, Dey N, et al. Med Image Anal. 2022;81:102538. doi:10.1016/j.media.2022.102538 Portable, low-field magnetic resonance imaging enables highly accessible and dynamic bedside evaluation of ischemic stroke. Yuen MM, Prabhat AM, Mazurek MH, et al. Sci Adv. 2022;8(16):eabm3952. doi:10.1126/sciadv.abm3952 Safety of Bedside Portable Low-Field Brain MRI in ECMO Patients Supported on Intra-Aortic Balloon Pump. Wilcox C, Acton M, Rando H, et al. Diagnostics (Basel). 2022;12(11):2871. Published 2022 Nov 19. doi:10.3390/diagnostics 12112871 Bedside detection of intracranial midline shift using portable magnetic resonance imaging. Sheth KN, Yuen MM, Mazurek MH, et al. Sci Rep. 2022;12(1):67. Published 2022 Jan 7. doi:10.1038/s41598-021-03892-7 HYPERFINE.